{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:37:41Z","timestamp":1794245861301,"version":"4.9.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Italian Minister of Health grant \u201cMissione 6\/componente 2\/Investimento: 2.1 \u201cRafforzamento e potenziamento della ricerca biomedica del SSN\u201d, supported by Unione europea \u2013 Next Generation EU","award":["PNRR-POC-2022-12375713"],"award-info":[{"award-number":["PNRR-POC-2022-12375713"]}]},{"name":"Italian Ministry of Health Ricerca Corrente funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs), such as anti-Cytotoxic T-Lymphocyte Antigen 4(CTLA-4) and anti-Programmed cell death protein 1 (PD-1) agents, have improved the prognosis of patients with metastatic melanoma. However, a proportion of patients develop resistance to these treatments, leading to a poor prognosis. Therefore, identifying potential non invasive and easy to measure biomarkers is crucial for guiding treatment strategies in patients with metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective single-center study was conducted involving patients with metastatic stage IV melanoma who received first-line treatment with anti-CTL4 and\/or anti-PD-1 agents. The patients were categorized into two groups on the basis of their 1-year overall survival (OS): those with good outcomes (long-term OS\u2009\u2265\u20091 year) and those with poor outcomes (short-term OS\u2009&lt;\u20091 year). Peripheral metabolomics was performed using baseline sera from 132 patients via 600\u00a0MHz Nuclear Magnetic Resonance (NMR) spectroscopy. Enriched functional analysis was conducted to identify the metabolic pathways in which significant metabolites were involved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sparse partial least squares discriminant analysis (sPLS-DA) and loading plots obtained by analyzing the metabolomics profiles of samples collected before ICI treatment revealed significantly different levels of metabolites between the two groups (long-term OS vs. short-term OS). Specifically, lactate, tryptophan and valine significantly predicted the OS of the whole study population subjected to ICI immunotherapy; alanine, asparagine, glutathione, histidine, isoleucine and phenylalanine significantly predicted the OS of patients treated with ipilimumab; glucose, glutamine, histidine and proline significantly predicted the OS of patients treated with nivolumab; and lactate, lysine and proline significantly predicted the OS of patients treated with ipilimumab plus nivolumab. Notably, tryptophan levels were correlated with treatment response in the overall patient group, whereas histidine and lactate levels were associated with response in patients treated with ipilimumab and with ipilimumab plus nivolumab, respectively. Interestingly, higher pretreatment levels of histidine were commonly found in long-term OS subgroups of patients treated with ipilimumab, nivolumab or ipilimumab plus nivolumab. Interestingly, considering only those metabolites that predict OS after univariate analysis, higher histidine, and lower lactate and proline levels resulted as associated with favorable OS in at least two patient cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, this exploratory liquid biopsy study revealed a strong correlation between the pretreatment levels of some metabolites and the OS of patients with metastatic stage IV melanoma treated with anti-CTL4 and\/or anti-PD-1 antibodies in the first-line setting and revealed the potential of these molecules to predict outcomes and define personalized management and treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03378-8","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:17:56Z","timestamp":1744258676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy"],"prefix":"10.1186","volume":"44","author":[{"given":"Susan","family":"Costantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palmina","family":"Bagnara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Renza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Affatato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Tuffanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"3378_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","volume":"133","author":"C Luther","year":"2019","unstructured":"Luther C, Swami U, Zhang J, Milhem M, Zakharia Y. Advanced stage melanoma therapies: detailing the present and exploring the future. Crit Rev Oncol Hematol. 2019;133:99\u2013111.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"3378_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"12","key":"3378_CR3","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"3378_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"10304","key":"3378_CR5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002\u201314.","journal-title":"Lancet"},{"key":"3378_CR6","doi-asserted-by":"crossref","unstructured":"Regan MM, Mantia CM, Werner L, Tarhini AA, Larkin J, Stephen Hodi F et al. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in checkmate 067. J Immunother Cancer. 2021;9(11).","DOI":"10.1136\/jitc-2021-003743"},{"key":"3378_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8:34.","journal-title":"Biomark Res"},{"issue":"12","key":"3378_CR8","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908\u201318.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3378_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cncr.32506","volume":"126","author":"EK Bartlett","year":"2020","unstructured":"Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76\u201385.","journal-title":"Cancer"},{"key":"3378_CR10","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22:5487\u201396.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3378_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo D, Fordellone M, White A, Ottaviano M, Sparano F, Bailey M, et al. CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J Transl Med. 2023;21(1):610.","journal-title":"J Transl Med"},{"issue":"1","key":"3378_CR12","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-024-01954-6","volume":"9","author":"T Hu","year":"2024","unstructured":"Hu T, Liu CH, Lei M, Zeng Q, Li L, Tang H, et al. Metabolic regulation of the immune system in health and diseases: mechanisms and interventions. Signal Transduct Target Ther. 2024;9(1):268.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"3378_CR13","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1097\/MS9.0000000000001308","volume":"85","author":"N Aderinto","year":"2023","unstructured":"Aderinto N, Abdulbasit MO, Tangmi ADE, Okesanya JO, Mubarak JM. Unveiling the growing significance of metabolism in modulating immune cell function: exploring mechanisms and implications; a review. Ann Med Surg (Lond). 2023;85(11):5511\u201322.","journal-title":"Ann Med Surg (Lond)"},{"key":"3378_CR14","doi-asserted-by":"crossref","unstructured":"Vilbert M, Koch EC, Rose AAN, Laister RC, Gray D, Sotov V et al. Analysis of the Circulating metabolome of patients with cutaneous, mucosal and uveal melanoma reveals distinct metabolic profiles with implications for response to immunotherapy. Cancers (Basel). 2023;15(14).","DOI":"10.3390\/cancers15143708"},{"key":"3378_CR15","doi-asserted-by":"publisher","first-page":"1331215","DOI":"10.3389\/fonc.2024.1331215","volume":"14","author":"W Wang","year":"2024","unstructured":"Wang W, Zhen S, Ping Y, Wang L, Zhang Y. Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring. Front Oncol. 2024;14:1331215.","journal-title":"Front Oncol"},{"issue":"1","key":"3378_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bbcan.2018.04.009","volume":"1870","author":"AK Kaushik","year":"2018","unstructured":"Kaushik AK, DeBerardinis RJ. Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 2018;1870(1):2\u201314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3378_CR17","doi-asserted-by":"publisher","first-page":"1110104","DOI":"10.3389\/fonc.2022.1110104","volume":"12","author":"S Costantini","year":"2022","unstructured":"Costantini S, Di Gennaro E, Capone F, De Stefano A, Nasti G, Vitagliano C, et al. Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection. Front Oncol. 2022;12:1110104.","journal-title":"Front Oncol"},{"key":"3378_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.copbio.2016.08.001","volume":"43","author":"JL Markley","year":"2017","unstructured":"Markley JL, Bruschweiler R, Edison AS, Eghbalnia HR, Powers R, Raftery D, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43:34\u201340.","journal-title":"Curr Opin Biotechnol"},{"issue":"8","key":"3378_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11306-018-1398-9","volume":"14","author":"AWL Bayci","year":"2018","unstructured":"Bayci AWL, Baker DA, Somerset AE, Turkoglu O, Hothem Z, Callahan RE, et al. Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics. 2018;14(8):105.","journal-title":"Metabolomics"},{"key":"3378_CR20","doi-asserted-by":"crossref","unstructured":"Costantini S, Madonna G, Di Gennaro E, Capone F, Bagnara P, Capone M et al. New insights into the identification of metabolites and cytokines predictive of outcome for patients with severe SARS-CoV-2 infection showed similarity with cancer. Int J Mol Sci. 2023;24(5).","DOI":"10.3390\/ijms24054922"},{"issue":"W1","key":"3378_CR21","doi-asserted-by":"publisher","first-page":"W388","DOI":"10.1093\/nar\/gkab382","volume":"49","author":"Z Pang","year":"2021","unstructured":"Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between Raw spectra and functional insights. Nucleic Acids Res. 2021;49(W1):W388\u201396.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"3378_CR22","first-page":"D801","volume":"41","author":"DS Wishart","year":"2013","unstructured":"Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0\u2013The human metabolome database in 2013. Nucleic Acids Res. 2013;41(Database issue):D801\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3378_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355\u201377.","journal-title":"Cell Metab"},{"issue":"6","key":"3378_CR24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"6","key":"3378_CR25","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/1078-0432.CCR-21-3114","volume":"28","author":"PL Triozzi","year":"2022","unstructured":"Triozzi PL, Stirling ER, Song Q, Westwood B, Kooshki M, Forbes ME, et al. Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients\u2019 response to Anti-PD-1 immune checkpoint Blockade. Clin Cancer Res. 2022;28(6):1192\u2013202.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3378_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/pcmr.12661","volume":"31","author":"GM Fischer","year":"2018","unstructured":"Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, Davies MA. Metabolic strategies of melanoma cells: mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res. 2018;31(1):11\u201330.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3378_CR27","doi-asserted-by":"crossref","unstructured":"Warrier G, Lanceta L, Imbert-Fernandez Y, JA C. Inhibition of glucose metabolism through treatment of BRAF mutated metastatic melanoma with Vemurafenib. J Clin Oncol. 2019;37(15 supp).","DOI":"10.1200\/JCO.2019.37.15_suppl.e21005"},{"key":"3378_CR28","doi-asserted-by":"publisher","first-page":"1063423","DOI":"10.3389\/fonc.2022.1063423","volume":"12","author":"Y Xu","year":"2022","unstructured":"Xu Y, Hao X, Ren Y, Xu Q, Liu X, Song S, et al. Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma. Front Oncol. 2022;12:1063423.","journal-title":"Front Oncol"},{"issue":"1","key":"3378_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/imr.12846","volume":"295","author":"PJ Siska","year":"2020","unstructured":"Siska PJ, Singer K, Evert K, Renner K, Kreutz M. The immunological Warburg effect: can a metabolic-tumor-stroma score (MeTS) guide cancer immunotherapy? Immunol Rev. 2020;295(1):187\u2013202.","journal-title":"Immunol Rev"},{"issue":"9","key":"3378_CR30","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/2326-6066.CIR-16-0072","volume":"4","author":"ML Ascierto","year":"2016","unstructured":"Ascierto ML, McMiller TL, Berger AE, Danilova L, Anders RA, Netto GJ, et al. The intratumoral balance between metabolic and Immunologic gene expression is associated with Anti-PD-1 response in patients with renal cell carcinoma. Cancer Immunol Res. 2016;4(9):726\u201333.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3378_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.cell.2019.08.012","volume":"179","author":"M Harel","year":"2019","unstructured":"Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell. 2019;179(1):236\u201350. e18.","journal-title":"Cell"},{"key":"3378_CR32","doi-asserted-by":"crossref","unstructured":"Daneshmandi S, Wegiel B, Seth P. Blockade of lactate Dehydrogenase-A (LDH-A) improves efficacy of Anti-Programmed cell Death-1 (PD-1) therapy in melanoma. Cancers (Basel). 2019;11(4).","DOI":"10.3390\/cancers11040450"},{"issue":"5","key":"3378_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/CMR.0000000000000181","volume":"25","author":"A Shimizu","year":"2015","unstructured":"Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res. 2015;25(5):399\u2013405.","journal-title":"Melanoma Res"},{"key":"3378_CR34","doi-asserted-by":"crossref","unstructured":"Badawy AA. Tryptophan metabolism and disposition in cancer biology and immunotherapy. Biosci Rep. 2022;42(11).","DOI":"10.1042\/BSR20221682"},{"key":"3378_CR35","doi-asserted-by":"crossref","unstructured":"Hubkova B, Valko-Rokytovska M, Cizmarova B, Zabavnikova M, Marekova M, Birkova A. Tryptophan: its metabolism along the kynurenine, serotonin, and Indole pathway in malignant melanoma. Int J Mol Sci. 2022;23(16).","DOI":"10.3390\/ijms23169160"},{"issue":"32","key":"3378_CR36","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","volume":"36","author":"TC Mitchell","year":"2018","unstructured":"Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, Open-Label phase I\/II trial (ECHO-202\/KEYNOTE-037). J Clin Oncol. 2018;36(32):3223\u201330.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3378_CR37","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083\u201397.","journal-title":"Lancet Oncol"},{"issue":"1\u20133","key":"3378_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0014-5793(01)03319-1","volume":"511","author":"A Slominski","year":"2002","unstructured":"Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Wortsman J. Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. FEBS Lett. 2002;511(1\u20133):102\u20136.","journal-title":"FEBS Lett"},{"issue":"1","key":"3378_CR39","doi-asserted-by":"publisher","first-page":"2204753","DOI":"10.1080\/2162402X.2023.2204753","volume":"12","author":"JD Oldan","year":"2023","unstructured":"Oldan JD, Giglio BC, Smith E, Zhao W, Bouchard DM, Ivanovic M, et al. Increased Tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III\/IV melanoma. Oncoimmunology. 2023;12(1):2204753.","journal-title":"Oncoimmunology"},{"key":"3378_CR40","doi-asserted-by":"crossref","unstructured":"Azuma K, Xiang H, Tagami T, Kasajima R, Kato Y, Karakawa S et al. Clinical significance of plasma-free amino acids and Tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. J Immunother Cancer. 2022;10(5).","DOI":"10.1136\/jitc-2021-004420"},{"key":"3378_CR41","doi-asserted-by":"publisher","first-page":"949745","DOI":"10.3389\/fphar.2022.949745","volume":"13","author":"C Yan","year":"2022","unstructured":"Yan C, Wu D, Gan L, Wang J, Yang W, Xu B. Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1\/PD-L1 immunotherapy. Front Pharmacol. 2022;13:949745.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3378_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1017\/S0007114511005289","volume":"108","author":"YC Niu","year":"2012","unstructured":"Niu YC, Feng RN, Hou Y, Li K, Kang Z, Wang J, et al. Histidine and arginine are associated with inflammation and oxidative stress in obese women. Br J Nutr. 2012;108(1):57\u201361.","journal-title":"Br J Nutr"},{"issue":"6","key":"3378_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00535-016-1261-6","volume":"52","author":"K Uchiyama","year":"2017","unstructured":"Uchiyama K, Yagi N, Mizushima K, Higashimura Y, Hirai Y, Okayama T, et al. Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol. 2017;52(6):677\u201394.","journal-title":"J Gastroenterol"},{"issue":"10","key":"3378_CR44","doi-asserted-by":"publisher","first-page":"e0240849","DOI":"10.1371\/journal.pone.0240849","volume":"15","author":"NJ Taylor","year":"2020","unstructured":"Taylor NJ, Gaynanova I, Eschrich SA, Welsh EA, Garrett TJ, Beecher C, et al. Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment. PLoS ONE. 2020;15(10):e0240849.","journal-title":"PLoS ONE"},{"key":"3378_CR45","doi-asserted-by":"publisher","first-page":"678753","DOI":"10.3389\/fmolb.2021.678753","volume":"8","author":"X Nie","year":"2021","unstructured":"Nie X, Xia L, Gao F, Liu L, Yang Y, Chen Y, et al. Serum metabolite biomarkers predictive of response to PD-1 Blockade therapy in Non-Small cell lung cancer. Front Mol Biosci. 2021;8:678753.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"3378_CR46","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/s41556-024-01503-x","volume":"26","author":"H Zhang","year":"2024","unstructured":"Zhang H, Liu J, Yuan W, Zhang Q, Luo X, Li Y, et al. Ammonia-induced lysosomal and mitochondrial damage causes cell death of effector CD8(+) T cells. Nat Cell Biol. 2024;26(11):1892\u2013902.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"3378_CR47","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41417-024-00851-y","volume":"31","author":"Z Li","year":"2024","unstructured":"Li Z, Lin J, Yin P. Ammonia death: a novel potential strategy to augment immunotherapy in cancer. Cancer Gene Ther. 2024;31(12):1751\u20133.","journal-title":"Cancer Gene Ther"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03378-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03378-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T04:18:03Z","timestamp":1744258683000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03378-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3378"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03378-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Istituto Nazionale Tumori IRCCS Fondazione Pascale (protocol code: 33\/17 OSS, date of approval: 10\/1\/2018). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following competing interests: P.A.A.: Stock and Other Ownership Interests: PrimeVax. Consulting or Advisory Role: Bristol Myers Squibb, Roche\/Genentech, Merck Sharp & Dohme, Novartis, Array BioPharma, Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore Technologies, Seattle Genetics, ITeos Therapeutics, Medicenna, Bio-Al Health, ValoTx. Research Funding: Bristol Myers Squibb (Inst), Roche\/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst), Pfizer (Inst). Travel, Accommodations, Expenses: Merck Sharp & Dohme, Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}